Gil Roth06.27.11
Evotec AG has received a milestone payment for reaching specific success criteria in an ion channel research collaboration with Ono Pharmaceutical Co. This project was initiated in October 2009 to identify small molecules targeting an ion channel implicated in cardiovascular, CNS and urological diseases. The companies have successfully identified multiple compounds meeting various criteria in activity, selectivity and pharmacokinetic characteristics.
Evotec and Ono will continue this research collaboration until April 2012 and enter into lead optimization with the goal to generate new chemical entities, which will have the potential to become new drug candidates. Ono has a worldwide right to develop and commercialize compounds generated by Evotec in this collaboration.
Dr Mario Polywka, chief operating officer of Evotec, commented, "We are delighted to deliver high value molecules to our partner Ono and to expand our collaboration. We enjoy a very successful and close relationship. This achievement clearly demonstrates the value we bring to our alliance partners in the area of drug discovery. We look forward to continuing working closely with our colleagues at Ono."
Evotec and Ono will continue this research collaboration until April 2012 and enter into lead optimization with the goal to generate new chemical entities, which will have the potential to become new drug candidates. Ono has a worldwide right to develop and commercialize compounds generated by Evotec in this collaboration.
Dr Mario Polywka, chief operating officer of Evotec, commented, "We are delighted to deliver high value molecules to our partner Ono and to expand our collaboration. We enjoy a very successful and close relationship. This achievement clearly demonstrates the value we bring to our alliance partners in the area of drug discovery. We look forward to continuing working closely with our colleagues at Ono."